Management of toenail onychomycosis with 2% butenafine and 20% urea cream: A placebo-controlled, double-blind study

Journal of Dermatology

Volumn 25, Issue 10, 1998, Pages 648-652

  Syed, Tanweer A ^a   Ahmadpour, Oliver Abbas ^b   Ahmad, Seyed Ali ^c   Shamsi, Sadaf ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c Windsor High School   (United States)

^d Municipal Dispensary   (Pakistan)

Author keywords

Butenafine; Keratinolysis; Onychomycosis; Pharmaceutical creams

Indexed keywords

BUTENAFINE; PLACEBO; POTASSIUM HYDROXIDE; UREA;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG TOLERABILITY; FEMALE; FUNGUS CULTURE; FUNGUS IDENTIFICATION; GOOD CLINICAL PRACTICE; HALLUX; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; ONYCHOMYCOSIS; PAKISTAN; PRACTICE GUIDELINE; PROTECTIVE CLOTHING; RANDOMIZED CONTROLLED TRIAL; TOE; TOPICAL DRUG ADMINISTRATION;

EID: 0031798474     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1998.tb02474.x     Document Type: Article

References (15)

1. Summerbell RC: Epidemiology and ecology of onychomycosis, Dermatology, 194 (1 suppl): 32-36, 1997.
2. Midgley G, Moore MK, Cook JC, Phan QG: Mycology of nail disorders, J Am Acad Dermatol, 31: s68-s74, 1994.
3. Baran RL, Aly R: Diagnosis and new treatments in the management of onychomycosis, in Aly R, Beutner KR, Maibach H (eds): Cutaneous Infection and Therapy, Marcel Dekker, New York, 1997, pp 149-156.
4. Crissey, Lang Heidi, Parish LC: Manual of Medical Mycology, Blackwell Sciences, Cambridge, MA, 1995, pp 19-35.
5. Brennan B, Leyden JJ: Overview of topical therapy for common superficial fungal infections and the role of new topical agents, J Am Acad Dermatol, 36: s3-s8, 1997.
6. Fukushiro R, Urabe H, Kagawa S, et al: Butenafine hydrochloride, a new antifungal agent; Clinical and experimental study, in Yamaguchi H, Kobayashi GS, Takahashi H (eds): Recent Progress in Antifungal Chemotherapy, Marcel Dekker, New York, 1992, pp 147-157.
7. Tschen E, Elewski B, Gorsulowsky DC, Pariser DM: Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream, J Am Acad Dermatol, 36: s9-s14, 1997.
8. Rashid A, Richardson MD: Pathogenesis of dermatophytosis, in Aly R, Beutner KR, Maibach H (eds): Cutaneous Infection and Therapy, Marcel Dekker, New York, 1997, pp 127-138.
9. Degreef HJ, DeDoncker PRG: Current therapy of dermatophytosis, J Am Acad Dermatol, 31: s25-s30, 1994.
10. Robert DT: Oral therapeutic agents in fungal nail disease, J Am Acad Dermatol, 31: s78-s81, 1994.
11. Drake LA, Shear NH, Ariette JP, et al: Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial, J Am Acad Dermatol, 37: 740-745, 1997.
12. Del Rosso JQ: Advances in the treatment of superficial fungal infections: Focus on onychomycosis and dry tinea pedis, J Am Osteopath Assoc, 6: 339-346, 1997.
13. Ernst TM, Hopfenmüller W: Clinical experience with bifonazole/urea, in Nolting S, Korting HC (eds): Onychomycoses, Local Antimycotic Treatment, Springer-Verlag, Berlin, Heidelberg, 1990, pp 94-101.
14. Torres-Rodríguez JM, Madrenys N, Nicolas MC: Non-traumatic topical treatment of onychomycosis with urea associated with bifonazole, Mycoses, 34: 499-504, 1991.
15. Friedman-Birnbaum R, Cohen A, Shemar A, et al: Treatment of onychomycosis: A randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin, Int J Dermatol, 36: 67-69, 1997.